Adaptin Bio, Inc. (APTN)

Adaptin Bio Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Selling, General & Admin	3.83	3.64	0.75	0.37	0.01
Research & Development	1.88	1.77	1.82	0.51	-
Operating Expenses	5.71	5.41	2.57	0.88	0.01
Operating Income	-5.71	-5.41	-2.57	-0.88	-0.01
Interest Expense	-0	-0.07	-0.34	-0.1	-
Other Non Operating Income (Expenses)	-	-0.01	-0.02	-	-
EBT Excluding Unusual Items	-5.71	-5.49	-2.93	-0.98	-0.01
Other Unusual Items	-	0.33	-0.19	-	-
Pretax Income	-5.71	-5.17	-3.12	-0.98	-0.01
Net Income	-5.71	-5.17	-3.12	-0.98	-0.01
Net Income to Common	-5.71	-5.17	-3.12	-0.98	-0.01
Shares Outstanding (Basic)	9	8	3	-	-
Shares Outstanding (Diluted)	9	8	3	-	-
Shares Change (YoY)	119.06%	140.38%	-	-	-
EPS (Basic)	-0.67	-0.66	-0.96	-	-
EPS (Diluted)	-0.67	-0.66	-0.96	-	-
EBIT	-5.71	-5.41	-2.57	-0.88	-0.01

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 24, 2026

Data Sources Report a data error